ClinicalTrials.gg
CompletedNCT02262650Updated Oct 13, 2014

Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects

A Phase 1 interventional study of Telmisartan and Clopidogrel in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-13.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Study to investigate the relative bioavailability of concomitant administration of clopidogrel and telmisartan (Test 1) relative to the bioavailability of SR26334 alone (Reference 1), and relative to the bioavailability of telmisartan alone (Reference 2). And to investigate the bioavailability of SR26334 following administration of clopidogrel 30 minutes after intake of telmisartan (Test 2) relative to the bioavailability of SR26334 alone (Reference 1), and relative to the bioavailability of telmisartan alone (Reference 2)

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects according to the following criteria: based upon a complete medical history, the physical examination, vital signs (BP, HR), 12-lead , clinical laboratory tests
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation
  • Age >= 40 years
  • (BMI) >=18.5 and \<=29.9 kg/m2
  • Good venous status of forearms

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, heart rate, and ) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
  • Surgery of gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of an allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of any drugs, which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  • Participation in another trial with an drug within two months prior to administration or during the trial
  • Smoker (more than 10 cigarettes or three cigars or three pipes/day)
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation or loss of more than 400 mL within four weeks prior to administration or during the trial.
  • Excessive physical activities (within five days prior to administration or during the trial)
  • Any laboratory value outside the reference range of clinical relevance
  • History of hereditary fructose intolerance
  • Veins unsuited for i.v. puncture on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture, etc.)
  • Inability to comply with the dietary regimen of study centre
  • Inability to comply with the investigators instructions

For female subjects:

  • Pregnancy
  • Positive pregnancy test
  • No adequate e.g. oral contraceptives, sterilization, intrauterine device (IUD)
  • Inability to maintain this adequate contraception during the whole study period
  • Lactation period
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Telmisartan alone

    Drug: Telmisartan

  • Experimental
    Telmisartan + Clopidogrel (concomitantly)

    Drug: Telmisartan · Drug: Clopidogrel

  • Experimental
    Telmisartan + Clopidogrel (consecutively)

    Drug: Telmisartan · Drug: Clopidogrel

  • Active comparator
    Clopidogrel alone

    Drug: Clopidogrel

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-∞ (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: up to 72 hours post dose

  2. Cmax (maximum concentration of the analyte in plasma)

    Time frame: up to 72 hours post dose

Secondary outcomes

  1. Number of subjects with adverse events

    Time frame: up to 8 days after last drug administration

  2. Number of subjects with clinically significant findings in vital signs

    Time frame: up to 8 days after last drug administration

  3. Number of subjects with clinically significant findings in ECG

    Time frame: up to 8 days after last drug administration

  4. Number of subjects with clinically significant findings in labortory test

    Time frame: up to 8 days after last drug administration

  5. tmax (time from dosing to the maximum concentration of the analyte in plasma)

    Time frame: up to 72 hours post dose

  6. AUC0-tz (area under the concentration-time curve of the analytes in plasma over the time interval from 0 to the time of the last quantifiable data point)

    Time frame: up to 72 hours post dose

  7. λz (terminal rate constant in plasma)

    Time frame: up to 72 hours post dose

  8. t1/2 (terminal half-life of the analytes in plasma)

    Time frame: up to 72 hours post dose

  9. MRTpo (mean residence time of the analytes in the body after po administration)

    Time frame: up to 72 hours post dose

  10. CL/F (apparent clearance of the analytes in the plasma after extravascular administration)

    Time frame: up to 72 hours post dose

  11. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)

    Time frame: up to 72 hours post dose

  12. CLR, 0-24 (renal clearance of SR26334 in plasma from the time point t1 until the time point t2)

    Time frame: up to 72 hours post dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004 and a primary completion of May 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2014
First posted
Oct 13, 2014
Start
Apr 2004
Primary completionActual
May 2004
Last update
Oct 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02262650
Responsible party
Sponsor
First posted
Oct 13, 2014
Start date
Apr 2004
Primary completion
May 2004
Last update
Oct 13, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Clopidogrel

Start the discussion